Literature DB >> 28541963

CORRELATION OF STRUCTURAL AND FUNCTIONAL OUTCOME MEASURES IN A PHASE ONE TRIAL OF CILIARY NEUROTROPHIC FACTOR IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA.

Ferenc B Sallo1,2, Irene Leung1, Traci E Clemons3, Tunde Peto4,5, Emily Y Chew6, Daniel Pauleikhoff7, Alan C Bird8.   

Abstract

PURPOSE: Macular telangiectasia Type 2 is a bilateral, progressive, potentially blinding retinal disease characterized by both vascular and neurodegenerative signs. Both the area of the break in the ellipsoid zone seen in "en face" optical coherence tomographic (OCT) images and microperimetric focal retinal sensitivity loss have been proposed as potential measures of progression in macular telangiectasia. The authors aimed to assess the characteristics and interrelationship of these structural and functional disease markers from the data collected in a phase one clinical trial of ciliary neurotrophic factor in macular telangiectasia.
METHODS: Orthogonal topographic (en face) maps of the ellipsoid zone were generated from Heidelberg Spectralis OCT volume scans (15 × 10° area, 30-μm B-scan intervals) or Zeiss Cirrus HD-OCT 4000 512 × 128 cube scans. Mesopic microperimetry was performed on CenterVue MAIA perimeters, using a Goldmann III stimulus in a custom test grid. Structural and functional data were analyzed by two methods: by calculating aggregate loss and by simple thresholding. The alignment quality of structural and functional data was also evaluated.
RESULTS: Overall, the break area showed a good correlation with aggregate sensitivity loss (ρ = 0.834, P < 0.0001, 95% confidence interval 0.716-0.906) but also with the number of test points below a threshold value (e.g., <20 dB: ρ = 0.843, P < 0.0001, 95% confidence interval 0.755-0.902). Significant misalignment of the MAIA test grid was apparent in 13/48 visits of 7/14 eyes.
CONCLUSION: The authors found a good correlation between ellipsoid zone break area and function loss. En face OCT mapping of the ellipsoid zone appears to demonstrate structural change before mesopic microperimetry can detect a focal loss of retinal sensitivity. Thresholding offers a quick alternative to calculating aggregate sensitivity loss.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28541963      PMCID: PMC5700868          DOI: 10.1097/IAE.0000000000001706

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  14 in total

1.  The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema.

Authors:  Anjali S Maheshwary; Stephen F Oster; Ritchie M S Yuson; Lingyun Cheng; Francesca Mojana; William R Freeman
Journal:  Am J Ophthalmol       Date:  2010-05-10       Impact factor: 5.258

2.  Feasibility of Macular Integrity Assessment (MAIA) Microperimetry in Children: Sensitivity, Reliability, and Fixation Stability in Healthy Observers.

Authors:  Pete R Jones; Narmella Yasoubi; Marko Nardini; Gary S Rubin
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-11-01       Impact factor: 4.799

3.  Optical coherence tomography in unilateral resolved central serous chorioretinopathy.

Authors:  Chiara M Eandi; Juliet E Chung; Felice Cardillo-Piccolino; Richard F Spaide
Journal:  Retina       Date:  2005-06       Impact factor: 4.256

4.  Inner segment-outer segment junctional layer integrity and corresponding retinal sensitivity in dry and wet forms of age-related macular degeneration.

Authors:  Gennady Landa; Emily Su; Patricia M T Garcia; William H Seiple; Richard B Rosen
Journal:  Retina       Date:  2011-02       Impact factor: 4.256

5.  Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial.

Authors:  Emily Y Chew; Traci E Clemons; Tunde Peto; Ferenc B Sallo; Avner Ingerman; Weng Tao; Lawrence Singerman; Steven D Schwartz; Neal S Peachey; Alan C Bird
Journal:  Am J Ophthalmol       Date:  2014-12-19       Impact factor: 5.258

6.  A comparison of visual field sensitivity to photoreceptor thickness in retinitis pigmentosa.

Authors:  Nalini V Rangaswamy; Hemaxi M Patel; Kirsten G Locke; Donald C Hood; David G Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-10       Impact factor: 4.799

7.  The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia.

Authors:  Ferenc B Sallo; Tunde Peto; Catherine Egan; Ute E K Wolf-Schnurrbusch; Traci E Clemons; Mark C Gillies; Daniel Pauleikhoff; Gary S Rubin; Emily Y Chew; Alan C Bird
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-29       Impact factor: 4.799

8.  Patient selection for macular translocation surgery using the scanning laser ophthalmoscope.

Authors:  Gildo Y Fujii; Eugene de Juan; Janet Sunness; Mark S Humayun; Dante J Pieramici; Tom S Chang
Journal:  Ophthalmology       Date:  2002-09       Impact factor: 12.079

9.  Photoreceptor outer segment abnormalities as a cause of blind spot enlargement in acute zonal occult outer retinopathy-complex diseases.

Authors:  Richard F Spaide; Hideki Koizumi; K Bailey Freund
Journal:  Am J Ophthalmol       Date:  2008-04-24       Impact factor: 5.258

Review 10.  Treatment for Macular Telangiectasia Type 2.

Authors:  Peter Charbel Issa; Elke H Kupitz; Tjebo F C Heeren; Frank G Holz
Journal:  Dev Ophthalmol       Date:  2015-10-26
View more
  11 in total

1.  LONGITUDINAL CORRELATION OF ELLIPSOID ZONE LOSS AND FUNCTIONAL LOSS IN MACULAR TELANGIECTASIA TYPE 2.

Authors:  Tjebo F C Heeren; Diána Kitka; Daniela Florea; Traci E Clemons; Emily Y Chew; Alan C Bird; Daniel Pauleikhoff; Peter Charbel Issa; Frank G Holz; Tunde Peto
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

2.  Association of Retinal Sensitivity With Optical Coherence Tomography Microstructure in Highly Myopic Patients.

Authors:  Un Chul Park; Chang Ki Yoon; Kunho Bae; Eun Kyoung Lee
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-10-03       Impact factor: 4.925

3.  Beyond Performance Metrics: Automatic Deep Learning Retinal OCT Analysis Reproduces Clinical Trial Outcome.

Authors:  Jessica Loo; Traci E Clemons; Emily Y Chew; Martin Friedlander; Glenn J Jaffe; Sina Farsiu
Journal:  Ophthalmology       Date:  2019-12-23       Impact factor: 12.079

4.  Global Connections to Study Idiopathic Macular Telangiectasia Type 2.

Authors:  Emily Y Chew; Martin Friedlander
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

5.  Deep learning-based classification and segmentation of retinal cavitations on optical coherence tomography images of macular telangiectasia type 2.

Authors:  Jessica Loo; Cindy X Cai; John Choong; Emily Y Chew; Martin Friedlander; Glenn J Jaffe; Sina Farsiu
Journal:  Br J Ophthalmol       Date:  2020-11-23       Impact factor: 4.638

6.  Photoreceptor Protection by Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF).

Authors:  Jianmin Lu; Lingyu Luo; Deqiang Huang; Xian Liu; Xin Xia; Zhengying Wang; Byron L Lam; Jinglin Yi; Rong Wen; Yiwen Li
Journal:  eNeuro       Date:  2018-04-20

7.  Performance of a Defect-Mapping Microperimetry Approach for Characterizing Progressive Changes in Deep Scotomas.

Authors:  Zhichao Wu; Roberta Cimetta; Emily Caruso; Robyn H Guymer
Journal:  Transl Vis Sci Technol       Date:  2019-08-01       Impact factor: 3.283

8.  Retinal cavitations in macular telangiectasia type 2 (MacTel): longitudinal structure-function correlations.

Authors:  Cindy X Cai; John Choong; Sina Farsiu; Stephanie J Chiu; Emily Y Chew; Glenn J Jaffe
Journal:  Br J Ophthalmol       Date:  2020-03-09       Impact factor: 4.638

Review 9.  Clinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease.

Authors:  Yesa Yang; Hannah Dunbar
Journal:  Ophthalmologica       Date:  2021-02-10       Impact factor: 3.250

10.  Deep longitudinal transfer learning-based automatic segmentation of photoreceptor ellipsoid zone defects on optical coherence tomography images of macular telangiectasia type 2.

Authors:  Jessica Loo; Leyuan Fang; David Cunefare; Glenn J Jaffe; Sina Farsiu
Journal:  Biomed Opt Express       Date:  2018-05-16       Impact factor: 3.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.